Results 51 to 60 of about 22,310 (212)

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

open access: yesClinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha   +4 more
wiley   +1 more source

The synthesis and structure of an n-terminal dodecanoic acid conjugate of a-conotoxin MII [PDF]

open access: yes, 2001
The alpha-conotoxin MII is a 16 amino acid long peptide toxin isolated from the marine snail, Conus magus. This toxin has been found to be a highly selective and potent inhibitor of neuronal nicotinic acetylcholine receptors of the subtype alpha3beta2 ...
David Craik   +15 more
core   +1 more source

Research into the Bioengineering of a Novel α-Conotoxin from the Milked Venom of Conus obscurus

open access: yes, 2022
The marine cone snail produces one of the fastest prey strikes in the animal kingdom. It injects highly efficacious venom, often causing prey paralysis and death within seconds.
Sean Wiere   +19 more
core   +1 more source

Effects of Selenocysteine Substitution on the Cyclotide Kalata B2

open access: yesChemBioChem, Volume 27, Issue 18, 28 September 2026.
Selenocysteine (Sec) substitution of any of the native complementary cysteine (Cys) residues of the cyclotide kalata B2 preserves the structure, cytotoxicity, and membrane‐binding activity while enhancing its folding efficiency. The study shows the conservative nature and folding benefit of selenocysteine replacement in kalata B2.
Ramoncito Luis B. de Boda   +5 more
wiley   +1 more source

NMR structure determination of a novel conotoxin, [Pro 7,13] αA-conotoxin Piva

open access: yes, 1997
A high-resolution solution conformation of a novel conotoxin, [Pro 7,13] αA-conotoxin P(IVA), GCCGSYPNAACHPCSCKDROSYCGQ-NH2, has been determined by two-dimensional 1H NMR methods and distance geometry calculations.
Kyou Hoon Han   +7 more
core   +1 more source

omega-Conotoxin GVIA binds to and blocks rat neuromuscular junction

open access: yes, 1994
The effect of omega-conotoxin GVIA, a specific blocker of N-type calcium channels, on the synaptic transmission at the mammalian neuromuscular junction is controversial. We have found that 125I-omega-conotoxin binds to rat tibialis muscle end-plate; that
L. La Maestra   +3 more
core   +1 more source

Solution structure of ω-conotoxin MVIIA using 2D NMR spectroscopy [PDF]

open access: yes, 1995
The solution structure of ω-conotoxin MVIIA (SNX-111), a peptide toxin from the fish hunting cone snail Conus magus and a high-affinity blocker of N-type calcium channels, was determined by 2D NMR spectroscopy.
Vladimir J. Basus   +7 more
core   +1 more source

Voltage-Gated Sodium Channel Inhibition by µ-Conotoxins

open access: yesToxins
µ-Conotoxins are small, potent pore-blocker inhibitors of voltage-gated sodium (NaV) channels, which have been identified as pharmacological probes and putative leads for analgesic development.
Kirsten L. McMahon   +2 more
doaj   +1 more source

Screening and Validation of Highly-Efficient Insecticidal Conotoxins from a Transcriptome-Based Dataset of Chinese Tubular Cone Snail

open access: yesToxins, 2017
Most previous studies have focused on analgesic and anti-cancer activities for the conotoxins identified from piscivorous and molluscivorous cone snails, but little attention has been devoted to insecticidal activity of conotoxins from the dominant ...
Bingmiao Gao   +5 more
doaj   +1 more source

Prolonging the Efficacy of Botulinum Toxin A Using a Novel Toxin Mimetic Complex and Peptide Formulation [PDF]

open access: yesJ Cosmet Dermatol
ABSTRACT Background Botulinum toxin type A (BTX‐A) is the cornerstone for treating dynamic wrinkles; however, it requires reinjection every 3–4 months. Adjunctive topical creams that mimic the effect of BTX‐A and enhance its action may prolong treatment intervals.
Kassem R   +4 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy